An Open-Label, Phase II, Study to Evaluate Biomarkers Associated with Response to Subsequent Therapies in Subjects with HER2-Positive Metastatic Breast Cancer Receiving Treatment with Trastuzumab in Combination with Lapatinib or Chemotherapy (EGF117165)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab
- Indications Breast cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms DB in 3L MBC
- Sponsors GlaxoSmithKline; Novartis
- 10 Oct 2017 Planned primary completion date changed from 1 Sep 2018 to 27 Mar 2018.
- 20 Jun 2017 Planned End Date changed from 1 Aug 2017 to 1 Sep 2018.
- 20 Jun 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Sep 2018.